Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tarsus Pharmaceuticals, Inc.

40.65
-0.4200-1.02%
Post-market: 40.650.00000.00%16:11 EDT
Volume:1.28M
Turnover:51.70M
Market Cap:1.71B
PE:-14.95
High:41.30
Open:41.07
Low:39.33
Close:41.07
Loading ...

Jeffrey Farrow, Officer, Reports Disposal of Tarsus Pharmaceuticals Inc. Common Shares

Reuters
·
19 Jun

Tarsus Pharmaceuticals Inc. Concluded Annual Stockholders Meeting

Reuters
·
19 Jun

Chief Medical Officer Elizabeth Yeu Reports Disposal of Common Shares in Tarsus Pharmaceuticals Inc

Reuters
·
18 Jun

Aziz Mottiwala, Chief Commercial Officer, Reports Disposal of Tarsus Pharmaceuticals Common Shares

Reuters
·
12 Jun

Tarsus Pharmaceuticals: Promising Outlook with Successful Xdemvy Launch and Strategic Growth Initiatives

TIPRANKS
·
04 Jun

Guggenheim Sticks to Its Buy Rating for Tarsus Pharmaceuticals (TARS)

TIPRANKS
·
02 Jun

Oppenheimer Adjusts Price Target on Tarsus Pharmaceuticals to $75 From $72, Maintains Outperform Rating

MT Newswires Live
·
02 Jun

Tarsus Pharmaceuticals : Oppenheimer Raises Target Price to $75 From $72

THOMSON REUTERS
·
02 Jun

Tarsus Pharmaceuticals Inc. to Participate in Upcoming William Blair 45th Annual Growth Stock Conference

Reuters
·
30 May

Tarsus Pharmaceuticals Coverage Assumed by HC Wainwright & Co. at Buy

Dow Jones
·
27 May

Promising Growth Trajectory of Tarsus Pharmaceuticals: Buy Rating Supported by Unique Product Positioning and Strong Market Presence

TIPRANKS
·
27 May

Tarsus Pharmaceuticals Inc : H.c. Wainwright Assumes Coverage With Buy Rating; Target Price $72

THOMSON REUTERS
·
27 May

Elanco Animal Health Sells Xdemvy Royalties To Blackstone in $295 Million Deal

Benzinga
·
06 May

Tarsus Pharmaceuticals Is Maintained at Neutral by Goldman Sachs

Dow Jones
·
05 May

Press Release: Elanco Sells Royalty and Milestone Rights for Lotilaner in Human Health to Blackstone; Accelerates Debt Paydown

Dow Jones
·
05 May

Tarsus Pharmaceuticals: Strong Financial Performance and Strategic Growth Initiatives Drive Buy Rating

TIPRANKS
·
03 May

Tarsus Pharmaceuticals Is Maintained at Buy by Guggenheim

Dow Jones
·
03 May

Stock Track | Tarsus Pharmaceuticals (TARS) Plunges 7.95% Pre-Market Despite Beating Q1 Earnings Estimates

Stock Track
·
02 May

Tarsus Pharmaceuticals Inc (TARS) Q1 2025 Earnings Call Highlights: Record Sales Surge and ...

GuruFocus.com
·
02 May

Tarsus Pharmaceuticals Reports Strong Q1 2025 Growth

TIPRANKS
·
02 May